Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma

Journal of Clinical Gastroenterology

Volumn 48, Issue 9, 2014, Pages 806-814

  Cheng, Jiwen ^a   Wang, Wanli ^a   Sun, Caihong ^b   Li, Muxing ^a   Wang, Bo ^a   Lv, Yi ^a,b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b 451 Hospital of PLA   (China)

Author keywords

Diagnosis; Hepatocellular carcinoma; Osteopontin; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; OSTEOPONTIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PREDICTIVE VALUE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84921505253     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000018     Document Type: Article

References (57)

1. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(suppl 4):5-13
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917
3. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59:225-249
4. La Vecchia C, Lucchini F, Franceschi S, et al. Trends in mortality from primary liver cancer in Europe. Eur J Cancer. 2000;36:909-915
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236
6. Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology. 2004;127: S104-S107
7. Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellular carcinoma serum markers. Semin Oncol. 2012;39:410-433
8. Bertino G, Neri S, Bruno CM, et al. Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 2011;102:363-371
9. Malaguarnera G, Paladina I, Giordano M, et al. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34:219-228
10. Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: largescale, multicentre study. Lancet Oncol. 2012;13:817-826
11. Zhou Y, Yin X, Ying J, et al. Golgi protein 73 versus alphafetoprotein as biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12:17
12. Lok AS, Sterling RK, Everhart JE, et al. Desgamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502
13. Marrero JA, Feng Z, Wang Y, et al. Alphafetoprotein, desgamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110-118
14. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979;16:885-993
15. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994;145:610-623
16. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer tumor progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94: 513-521
17. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184-190
18. Zhang CH, Xu GL, Jia WD, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2012;130:2685-2692
19. Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis. 2007;39:167-172
20. Lin F, Li Y, Cao J, et al. Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep. 2011;38: 5205-5210
21. Hsu HC, Tseng HJ, Lai PL, et al. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 1993;53:4691-4694
22. Kim J, Ki SS, Lee SD, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:2051-2059
23. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98:119-127
24. Cui BK, Zhang CQ, Zhang Y, et al. Osteopontin as potential biomarker of metastasis and recurrence for hepatocellular carcinoma. Ai Zheng. 2006;25:876-879
25. Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006; 132:709-717
26. Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55:483-490
27. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605
28. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25
29. The Cochrane Collaboration. Review Manager (RevMan) [Computer program].Version 5.1 Copenhagen: The Nordic Cochrane Center, 2011. Available at: http://www.cc-ims.net/Revman. Accessed March 22, 2011.
30. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834
31. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21: 1559-1573
32. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629-634
33. Peng SY, Ou YH, Chen WJ, et al. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol. 2005;26:1053-1061
34. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006;209:549-558
35. Chen RX, Xia YH, Cui JF, et al. Osteopontin, a single marker for predicting the prognosis of patients with tumor-nodemetastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol. 2010;25:1435-1442
36. Xue YH, Zhang XF, Dong QZ, et al. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 2010;52:2012-2022
37. Korita PV, Wakai T, Shirai Y, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol. 2008;39:1777-1783
38. Yang GH, Fan J, Xu Y, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist. 2008;13:1155-1165
39. Huang H, Zhang XF, Zhou HJ, et al. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010;101:1314-1319
40. Sieghart W, Wang X, Schmid K, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol. 2011;54:89-97
41. Yu MC, Lee YS, Lin SE, et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 2012;19:S455-S463
42. Tsai WC, Lee HS, Jin JS, et al. Association between Osteopontin and EGFR Expression with Clinicopathological Parameters in Hepatocellular Carcinoma. Chin J Physiol. 2012;55:412-420
43. Sun J, Xu HM, Zhou HJ, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:1-7
44. Zhang H, Ren N, Ye QH, et al. The prognostic significance of preoperative plasma level of osteopontin in combination with intercellular adhesion molecule-1 for patients with hepatocellular carcinoma. Zhong Hua Wai Ke Za Zhi. 2005;43:985-988
45. Kim SH, Chung YH, Yang SH, et al. Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. Korean J Hepatol. 2009;15:320-330
46. Zhou C, Zhou HJ, Zhang XF, et al. Postoperative serum osteopontin level is novel monitor for treatment response and tumor recurrence after resection of hepatitis Brelated hepatocellular carcinoma. Ann Surg Oncol. 2013;20: 929-937
47. Zhao L, Li T, Wang Y, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008;62:1056-1062
48. El-Din Bessa SS, Elwan NM, Suliman GA, et al. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res. 2010;41:541-547
49. Abu El Makarem MA, Abdel-Aleem A, Ali A, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol. 2011;10:296-305
50. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001; 323:157-162
51. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237-1256
52. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001;35:421-430
53. Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008;48:1834-1842
54. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997;3:605-611
55. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7:4060-4066
56. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59-67
57. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-1127.